StreetInsider.com News Articles

H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Wed, 09 Sep 2026 07:28:06 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating and $5.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst commented: "Novartis' ~150-patient, 54-week Phase 3 HARBOR study of del-desiran missed its placebo-controlled vHOT primary endpoint after MARINA had shown ~40% mean DMPK mRNA reduction, splicing correction and an approximately 2-3-second vHOT improvement at Year 1. That early functional magnitude is similar to the ~3-second vHOT changes subsequently reported with Dyne's (DYN; Ghosh; Buy) z-basivarsen and PepGen's (PEPG; Ghosh; Buy) PGN-EDODM1. We believe the read-through is particularly relevant for Sarepta because the marketed DMD story has continued to lose support:

Jefferies: 'we can still see at least a +25-50% stock move if SRPT shows competitive/superior 6-month splicing/vHOT data'

Tue, 08 Sep 2026 13:25:57 -0400

Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "Other thoughts/points: (1) A pot'l caveat is how SRP-1003's Phase I/II update could contain a Month 6 datacut, but seeing benefits on outcomes (e.g. QMT, 10MWR, MDHI, DM1-Active) may take longer to demonstrate efficacy. As such, reporting possibly only vHOT/splicing data in H2:26 could force the debate to linger. (2) Seeing a benefit on actual outcome measures (not vHOT) should drive uptake in the large 40K+ US patient TAM, as corroborated by our KOL checks (here, here, here) and del-desiran's own

Mizuho Defends Sarepta Therapeutics (SRPT)

Tue, 08 Sep 2026 10:53:35 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying the HARBOR sell-off is overdone.

The analyst commented, "We believe the sell-off (-10% vs. -1% XBI) due to Novartis' failed HARBOR Phase 3 study of del-desiran in DM1 is overdone. In our view, the press release contains little information about the Phase 3 results to draw broad negative readthroughs to Sarepta's SRP-1003. It's not clear why del-desiran missed the vHOT primary endpoint, but del-desiran seems to work, as Novartis noted that it showed evidence of clinical activity in secondary endpoints and exploratory analyses

Mizuho Defends Sarepta Therapeutics (SRPT)

Tue, 08 Sep 2026 10:53:35 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying the HARBOR sell-off is overdone.

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Tue, 08 Sep 2026 09:00:00 -0400

Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition

Now in its ninth year, program has awarded more than 150 scholarships

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne.

Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Tue, 08 Sep 2026 09:00:00 -0400

Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition

Now in its ninth year, program has awarded more than 150 scholarships

Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Mon, 31 Aug 2026 16:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET.

The presentation will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Mon, 31 Aug 2026 16:30:00 -0400

Form 13F-HR Sarepta Therapeutics, For: Jun 30

Fri, 14 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26923914.html

Form 13F-HR Sarepta Therapeutics, For: Jun 30

Fri, 14 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26923914.html

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC

Thu, 13 Aug 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20260813/26919605.html

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC

Thu, 13 Aug 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20260813/26919605.html

Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26889179.html

Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26889179.html

Sarepta Therapeutics (SRPT) PT Lowered to $35 at Oppenheimer

Thu, 06 Aug 2026 08:37:56 -0400

Oppenheimer analyst Andreas Argyrides lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $35.00 (from $37.00) while maintaining a Outperform rating.

Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue

Wed, 05 Aug 2026 16:35:07 -0400

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $0.64, $0.42 better than the analyst estimate of $0.22. Revenue for the quarter came in at $401.3 million versus the consensus estimate of $383 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

Form 8-K Sarepta Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874037.html

Form 8-K Sarepta Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874037.html

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026.

“As I begin my

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

“As I begin my

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

“As I begin my

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

“As I begin my

Form 10-Q Sarepta Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260805/AJ22W22FZW2R52ZK222C22YJEUVDYZ22Z282

Filed on: August 5, 2026

Form 10-Q Sarepta Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260805/AJ22W22FZW2R52ZK222C22YJEUVDYZ22Z282

Filed on: August 5, 2026

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260731/26848923.html